Testing effectiveness (Phase 2)UnknownNCT05472610What this trial is testingStudy of Efficacy of BZ019 in Large B-cell LymphomaWho this might be right forLarge B-cell Lymphoma Shanghai Mengchao Cancer Hospital 36
Early research (Phase 1)Looking for participantsNCT07239323What this trial is testingIn VIVO CAR-T Therapy for Relapsed/Refractory Hematological MalignanciesWho this might be right forB-Acute Lymphoblastic LeukemiaB Cell Non-Hodgkin's LymphomaMultiple Myeloma Chongqing Precision Biotech Co., Ltd 24
Early research (Phase 1)Enrolling By InvitationNCT06518668What this trial is testingNKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus ErythematosusWho this might be right forSystemic Lupus Erythematosus Hospital for Special Surgery, New York 6
Early research (Phase 1)UnknownNCT03030976What this trial is testingCD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)Who this might be right forSystemic Lupus Erythematosus (SLE) Shanghai GeneChem Co., Ltd. 5
Testing effectiveness (Phase 2)Looking for participantsNCT05319314What this trial is testingLYL273 for Patients With Relapsed or Refractory mCRCWho this might be right forColorectal Cancer Lyell Immunopharma, Inc. 155
Testing effectiveness (Phase 2)Active Not RecruitingNCT04787263What this trial is testingCD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PMLWho this might be right forAcute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaPrimary Mediastinal Lymphoma Bambino Gesù Hospital and Research Institute 32
Very early researchActive Not RecruitingNCT06789081What this trial is testingGPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)Who this might be right forAlveolar Soft Part Sarcoma AHS Cancer Control Alberta 1
Not applicableStudy completedNCT05763563What this trial is testingExercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell ImmunotherapyWho this might be right forLymphomaLeukemiaMyeloma H. Lee Moffitt Cancer Center and Research Institute 20
Early research (Phase 1)Temporarily pausedNCT06792344What this trial is testingClinical Study of CD19 CAR-T in the Treatment of Refractory Systemic SclerosisWho this might be right forSystemic Sclerosis (SSc) The Children's Hospital of Zhejiang University School of Medicine 12
Testing effectiveness (Phase 2)Looking for participantsNCT07622940What this trial is testingDual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal AdenocarcinomaWho this might be right forRecurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease Beijing Biotech 36
Early research (Phase 1)Looking for participantsNCT06420089What this trial is testingCD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Who this might be right forT Cell Non-Hodgkin Lymphoma Vittoria Biotherapeutics 30
Not applicableLooking for participantsNCT06339255What this trial is testingItalian Observational Study on CAR-T Therapy for LymphomaWho this might be right forDiffuse Low Grade B-Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Mantle Cell Lymphoma+1 more Paolo Corradini 5,300
Early research (Phase 1)Study completedNCT02659943What this trial is testingT Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesWho this might be right forLymphoma, B-CellLymphoma, Non-hodgkins National Cancer Institute (NCI) 27
Testing effectiveness (Phase 2)Study completedNCT03744676What this trial is testingA Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)Who this might be right forLymphoma, Non-HodgkinLymphomaLymphoma, B-Cell+7 more Juno Therapeutics, a Subsidiary of Celgene 104
Not applicableNot Yet RecruitingNCT06142188What this trial is testingRelmacabtagene Autoleucel in Hematologic MalignanciesWho this might be right forLymphoma, B-CellLarge B-cell LymphomaFollicular Lymphoma Shanghai Ming Ju Biotechnology Co., Ltd. 150
Very early researchUnknownNCT05105867What this trial is testingCD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesWho this might be right forRelapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-hodgkin Lymphoma 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 15
Early research (Phase 1)UnknownNCT05210907What this trial is testingClinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic LeukemiaWho this might be right forB-cell Acute Lymphoblastic Leukemia Seoul National University Hospital 5
Not applicableWithdrawnNCT04275154What this trial is testingImmunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell TherapyWho this might be right forHematologic Neoplasms University of Nebraska
Early research (Phase 1)Looking for participantsNCT01853631What this trial is testingActivated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)Who this might be right forNon-Hodgkin LymphomaChronic Lymphocytic LeukemiaAcute Lymphocytic Leukemia Baylor College of Medicine 64
Testing effectiveness (Phase 2)Looking for participantsNCT05442515What this trial is testingCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesWho this might be right forB-NHLB-Non Hodgkin LymphomaAcute Lymphocytic Leukemia+8 more National Cancer Institute (NCI) 130